Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer
24/06/2025 13:30
June 24 (Reuters) - Cytodyn Inc CYDY.PK: CYTODYN ANNOUNCES FIRST PATIENT DOSED IN PHASE II ONCOLOGY TRIAL IN COLORECTAL CANCER Source text: ID:nGNX5NlHtp Further company coverage: CYDY.PK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer